Wed, August 7, 2024

Cory Kasimov Maintained (BBIO) at Buy with Decreased Target to $45 on, Aug 7th, 2024


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. with-decreased-target-to-45-on-aug-7th-2024.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Cory Kasimov of Evercore ISI Group, Maintained "BridgeBio Pharma, Inc." (BBIO) at Buy with Decreased Target from $50 to $45 on, Aug 7th, 2024.

Cory has made no other calls on BBIO in the last 4 months.



There are 4 other peers that have a rating on BBIO. Out of the 4 peers that are also analyzing BBIO, 0 agree with Cory's Rating of Hold.



These are the ratings of the 4 analyists that currently disagree with Cory


  • Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $43 on, Monday, August 5th, 2024
  • Josh Schimmer of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $70 on, Monday, July 1st, 2024
  • Geoff Meacham of "B of A Securities" Maintained at Strong Buy with Decreased Target to $42 on, Tuesday, June 25th, 2024
  • Eliana Merle of "UBS" Maintained at Strong Buy with Decreased Target to $47 on, Tuesday, May 28th, 2024

Publication Contributing Sources